



Fintepla in the UAE

The MoHAP named-patient coordination pathway — indicative 2026

PAEDIATRIC NEUROLOGY · DRAVET / LGS

The clinical situation

Fintepla (fenfluramine oral solution) is an FDA-approved antiseizure medicine indicated for seizures in Dravet syndrome and Lennox-Gastaut syndrome (LGS) in patients aged 2 years and older, manufactured by UCB. Dosing is twice daily, weight-based, titrated over several weeks. Fintepla carries risk of valvular heart disease and pulmonary arterial hypertension, so baseline and periodic paediatric-cardiology echocardiogram surveillance is mandatory (US REMS-equivalent). Eligibility anchors to clinical diagnosis (SCN1A confirmation for Dravet where relevant; clinical/EEG criteria for LGS) and a named UAE paediatric cardiologist committed to the surveillance schedule.

The pathway, 6 steps

- 1 Consultation with paediatric neurology.** Dravet or LGS diagnosis, SCN1A/EEG evidence, seizure history, and current antiseizure regimen documented.
- 2 Baseline cardiac assessment.** A UAE-based paediatric cardiologist performs a baseline echocardiogram and sets the surveillance cadence.
- 3 MoHAP named-patient application.** Physician or hospital pharmacy files clinical rationale, cardiac-surveillance plan, patient reference, and chain-of-custody plan (DoH/DHA as applicable).
- 4 US-side sourcing.** Reserve Meds coordinates with our US-licensed DSCSA-compliant specialty wholesale partner to secure Fintepla from UCB's authorised channel.
- 5 Shipment.** Chain-of-custody documentation travels with the bottle to the treating hospital pharmacy.
- 6 Arrival, dispensing & surveillance.** Weight-based titration starts under neurology; paediatric cardiology schedules follow-up echocardiograms.

Indicative economics

Reference US cash-pay range: USD 100,000–200,000 per year depending on body weight (drug-only reference; Reserve Meds provides a transparent delivered quote at intake).

Indicative first-dose timing

7–14 days from a complete MoHAP application and documented baseline echocardiogram to first dispensation, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your physician and MoHAP (or DoH/DHA) review, including the cardiac-surveillance plan required for Fintepla. **Logistics.** Shipment coordination to the prescribing hospital pharmacy, aligned with echocardiogram cadence. **Concierge case lead.** Named point

of contact for the family, neurology and cardiology teams. **We are a coordinator** — not the prescriber, not the dispensing pharmacy, and we do not perform echocardiograms. All clinical decisions remain with your treating paediatric neurologist and cardiologist.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Fintepla × UAE first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/fintepla-uae.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team